Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GOSS

GOSS - Gossamer Bio Inc Stock Price, Fair Value and News

$2.55-0.09 (-3.41%)
Market Closed

24/100

GOSS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

24/100

GOSS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.16

Target 3M

$2.49

Target 6M

$2.3

GOSS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GOSS Price Action

Last 7 days

-6.9%

Last 30 days

-20.6%

Last 90 days

5.4%

Trailing 12 Months

177.2%

GOSS RSI Chart

GOSS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GOSS Valuation

Market Cap

590.2M

Price/Earnings (Trailing)

-3.78

Price/Sales (Trailing)

13.4

EV/EBITDA

-4.04

Price/Free Cashflow

-3.72

GOSS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.16

Target 3M

$2.49

Target 6M

$2.3

GOSS Fundamentals

GOSS Revenue

Revenue (TTM)

44.1M

Rev. Growth (Yr)

40.23%

Rev. Growth (Qtr)

15.71%

GOSS Earnings

Earnings (TTM)

-156.2M

Earnings Growth (Yr)

-56.55%

Earnings Growth (Qtr)

-25.99%

GOSS Profitability

EBT Margin

-349.30%

Return on Equity

189.67%

Return on Assets

-74.78%

Free Cashflow Yield

-26.86%

GOSS Investor Care

Shares Dilution (1Y)

2.14%

Diluted EPS (TTM)

-0.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025124.6M40.2M44.1M0
2024000114.7M
20230000
20220000
20210000
20205.0M4.5M4.0M3.4M
20190005.6M
20180001.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Gossamer Bio Inc

GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
 CEO
 WEBSITEgossamerbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES178

Gossamer Bio Inc Frequently Asked Questions

GOSS is the stock ticker symbol of Gossamer Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Gossamer Bio Inc is 590.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check GOSS's fair value in chart for subscribers.

The fair value guage provides a quick view whether GOSS is over valued or under valued. Whether Gossamer Bio Inc is cheap or expensive depends on the assumptions which impact Gossamer Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GOSS.

As of Wed Jan 28 2026, GOSS's PE ratio (Price to Earnings) is -3.78 and Price to Sales (PS) ratio is 13.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GOSS PE ratio will change depending on the future growth rate expectations of investors.